Compare EFSCP & WGSWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Enterprise Financial Services Corporation Depositary Shares Each Representing a 1/40th Interest in a Share of 5% Fixed Rate Non-Cumulative Perpetual Preferred Stock Series A
Current Price
| Metric | EFSCP | WGSWW |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | 1256 | 1000 |
| Industry | Major Banks | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | EFSCP | WGSWW |
|---|---|---|
| Price | $20.51 | $0.02 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | ★ 36.6K |
| Earning Date | N/A | 02-18-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $305,450,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 50.79 |
| 52 Week Low | N/A | $0.17 |
| 52 Week High | N/A | $0.21 |
| Indicator | EFSCP | WGSWW |
|---|---|---|
| Relative Strength Index (RSI) | 56.21 | 35.22 |
| Support Level | $19.44 | $0.01 |
| Resistance Level | $20.68 | $0.02 |
| Average True Range (ATR) | 0.32 | 0.00 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 81.43 | 22.52 |
Enterprise Financial Services Corporation is a financial holding company. It offers banking and wealth management services to individuals and business customers located in Arizona, California, Florida, Kansas, Missouri, Nevada, and New Mexico, in addition to loan and deposit production offices throughout the United States. The company offers a broad range of business and personal banking services including wealth management services. Lending services include commercial and industrial, commercial real estate, real estate construction and development, residential real estate and consumer loans.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.